BIO-TECHNE Corp (NASDAQ: TECH) CEO exercises 35,000 options, 28,686 shares withheld
Rhea-AI Filing Summary
Bio-Techne Corp CEO Kim Kelderman exercised stock options for 35,000 shares of common stock at an exercise price of $47.60 per share on 2026-07-28. He acquired these shares directly and had 28,686 shares of common stock withheld at $72.07 per share to pay the option exercise price or related tax liabilities. He continues to hold multiple stock option and restricted stock unit awards with various exercise prices, vesting dates and expirations.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 6,314 shares
Net Buy
19 txns
Insider
Kelderman Kim
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1 | 35,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 35,000 | $47.60 | $1.67M |
| Exercise Price or Tax Liability | Common Stock | 28,686 | $72.07 | $2.07M |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Performance Restricted Stock Units F2, F3 | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F4 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F5 | -- | -- | -- |
| holding | Performance Restricted Stock Units F2, F3 | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F6 | -- | -- | -- |
| holding | Performance Restricted Stock Units F2, F7 | -- | -- | -- |
| holding | Restricted Stock Units F2, F8 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F9 | -- | -- | -- |
| holding | Performance Restricted Stock Units F2, F10 | -- | -- | -- |
| holding | Restricted Stock Units F2, F11 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F12 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 141,668 shares (Direct);
Common Stock — 72,113 shares (Direct);
Stock Options (Right to Buy) — 307,975 shares (Direct);
Performance Restricted Stock Units — 140,265 shares (Direct);
Performance Stock Options (Right to Buy) — 49,826 shares (Direct);
Restricted Stock Units — 52,441 shares (Direct)
Footnotes (12)
- F1. Fully exercisable.
- F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F3. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F4. Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
- F5. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
- F6. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
- F7. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F8. 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
- F9. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
- F10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F11. 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
- F12. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Key Figures
Options exercised: 35,000 shares
Exercise price: $47.60 per share
Shares withheld for exercise price or taxes: 28,686 shares
+3 more
6 metrics
Options exercised
35,000 shares
Stock options for common stock exercised on 2026-07-28 at $47.60 per share
Exercise price
$47.60 per share
Exercise price for 35,000 stock options exercised on 2026-07-28
Shares withheld for exercise price or taxes
28,686 shares
Common shares withheld on 2026-07-28 under transaction code F
Withholding transaction price
$72.07 per share
Per-share value applied to 28,686 withheld shares under code F
Option block expiring 2027-08-05
115,724 underlying shares
Stock option at $66.97 exercise price expiring 2027-08-05
Long-dated options expiring 2035-08-15
90,441 underlying shares
Stock options at $53.60 exercise price expiring 2035-08-15
Key Terms
Stock Option (Right to Buy), Performance Restricted Stock Units, exercise price, tax liability
4 terms
Stock Option (Right to Buy) financial
"The reporting person holds Stock Option (Right to Buy) awards on common stock."
Performance Restricted Stock Units financial
"Holdings include Performance Restricted Stock Units that may settle in Bio-Techne common stock."
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
exercise price financial
"Several option grants specify an exercise price, such as $47.60, $66.97 and $53.60 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
tax liability financial
"A code F transaction reflects payment of exercise price or tax liability by withholding common shares."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did BIO-TECHNE Corp (TECH) CEO Kim Kelderman report in this Form 4?
Kim Kelderman reported exercising stock options for 35,000 BIO-TECHNE common shares at $47.60 per share. He then had 28,686 shares withheld at $72.07 per share to cover the option exercise price or related tax liabilities, with no open-market sale reported.
How many BIO-TECHNE (TECH) stock options did Kim Kelderman exercise and at what price?
He exercised options covering 35,000 shares of BIO-TECHNE common stock at an exercise price of $47.60 per share. The exercise used a derivative transaction (code M) that converted stock options into directly held common shares on 2026-07-28.
Does this BIO-TECHNE (TECH) Form 4 show any open-market purchases or sales by the CEO?
No open-market purchases or sales are reported; there are no transactions with purchase (P) or sale (S) codes. Activity consists of a stock option exercise (code M) and a code F withholding transaction to satisfy the option exercise price or tax obligations.
Was Kim Kelderman’s BIO-TECHNE (TECH) trading under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmative, so these transactions are not reported as occurring under a Rule 10b5-1 trading plan. They are disclosed simply as an option exercise and related withholding event on 2026-07-28.
What BIO-TECHNE (TECH) option and RSU positions does Kim Kelderman still hold after this Form 4?
He continues to hold several derivative and RSU awards, including options over 115,724 underlying shares at $66.97 expiring 2027-08-05 and options over 90,441 shares at $53.60 expiring 2035-08-15, plus multiple performance and time-based restricted stock units.
What does SEC transaction code F mean in the BIO-TECHNE (TECH) CEO’s Form 4?
Transaction code F denotes “Payment of exercise price or tax liability by delivering or withholding securities.” In this filing, it applies to 28,686 BIO-TECHNE common shares withheld at $72.07 per share in connection with the option exercise on 2026-07-28.